1Departments of Internal Medicine, Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea
2Departments of Radiation Oncology, Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea
3Departments of Otorhinolaryngology, Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea
Copyright © 2015 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Stage |
Response |
Recurrent cases in | ||
---|---|---|---|---|
CR | PR | SD or NA | CR cases | |
IV (n=35) | 25 (71.4) | 8 (22.9) | 2 (5.4)a) | 6/25 (24.0) |
Values are presented as number (%). CR, complete response; PR, partial response; SD, stable disease; NA, not applicable.
a) Two patients were unavailable for response evaluation because one patient died due to septic shock during chemoradiation and another refused to continue chemoradiation because of grade IV emesis.
Adverse effect |
Grade |
|||
---|---|---|---|---|
≤ 2 | 3 | 4 | 5 | |
Hematologic adverse events | ||||
Anemia | 18 (51.4) | 2 (5.7) | 0 | 0 |
Neutropenia | 10 (28.6) | 2 (5.7) | 0 | 0 |
Thrombocytopenia | 10 (28.6) | 2 (5.7) | 0 | 0 |
Non-hematologic adverse events | ||||
Stomatitis | 6 (17.1) | 29 (82.9) | 0 | 0 |
Dysphagia | 31 (88.6) | 3 (8.6) | 0 | 0 |
Emesis | 8 (22.9) | 0 | 1 (2.3) | 0 |
Infection | 8 (22.9) | 4 (11.4) | 0 | 1 (2.3)a) |
Dermatitis | 20 (57.2) | 8 (22.9) | 0 | 0 |
Renal dysfunction | 5 (14.3) | 1 (2.3) | 0 | 0 |
Others | 8 (22.9) | 2 (5.7) | 1 (2.3) | 0 |
Persistent adverse events | ||||
Xerostomia | 25 (71.4) | 2 (5.7) | 0 | 0 |
Dysphagia | 20 (57.1) | 0 | 0 | 0 |
Neck fibrosis | 7 (20.0) | 0 | 0 | 0 |
Study | Chemotherapy protocol (radiation dose) | No. of patients | Disease control rate (CR+PR, %) | Overall survival (%) | Stage |
---|---|---|---|---|---|
Present study | Cisplatin 30 mg/m2 at days 1, 8 and 15 every 4 wk during RT (70-72 Gy) | 35 | 94.30 | 51.2 (3 yr) | IVa |
Homma et al. (2011) [15] | Weekly cisplatin 40 mg/m2 on 1, 2, 3, 5, 6, and 7 of RT (70 Gy) | 53 | 100 | 93.7 (2 yr) | II-IV |
Kose et al. (2011) [18] | Weekly cisplatin 30 mg/m2 during RT (50-70 Gy) | 32 | - | 75.0 (3 yr) | II-IV |
Otty et al. (2011) [17] | Cisplatin 40 mg/m2 for 6 wk | 62 | 88.70 | 64.5 (3 yr) | II-IV |
Characteristic | No. (%) |
---|---|
Median age (range, yr) | 65 (34-82) |
Gender | |
Male | 35 (100) |
Female | 0 |
ECOG performance status | |
0 | 9 (25.7) |
1 | 26 (74.3) |
Stage | |
IVa | 33 (94.3) |
IVb | 2 (5.7) |
Primary site | |
Oropharynx | 15 (42.9) |
Hypopharynx | 41 (40.0) |
Larynx | 3 (8.6) |
Oral cavity | 3 (8.6) |
Histological grade | |
Well differentiated | 8 (22.9) |
Moderately differentiated | 21 (60.0) |
Poorly differentiated | 5 (14.3) |
Undifferentiated | 1 (2.9) |
Smoking history | |
Current or Ex-smoker | 25 (71.4) |
Never-smoker | 10 (28.6) |
HPV positivity (by DNA PCR) | 2/10 (20.0) |
Stage | Response |
Recurrent cases in | ||
---|---|---|---|---|
CR | PR | SD or NA | CR cases | |
IV (n=35) | 25 (71.4) | 8 (22.9) | 2 (5.4) |
6/25 (24.0) |
Adverse effect | Grade |
|||
---|---|---|---|---|
≤ 2 | 3 | 4 | 5 | |
Hematologic adverse events | ||||
Anemia | 18 (51.4) | 2 (5.7) | 0 | 0 |
Neutropenia | 10 (28.6) | 2 (5.7) | 0 | 0 |
Thrombocytopenia | 10 (28.6) | 2 (5.7) | 0 | 0 |
Non-hematologic adverse events | ||||
Stomatitis | 6 (17.1) | 29 (82.9) | 0 | 0 |
Dysphagia | 31 (88.6) | 3 (8.6) | 0 | 0 |
Emesis | 8 (22.9) | 0 | 1 (2.3) | 0 |
Infection | 8 (22.9) | 4 (11.4) | 0 | 1 (2.3) |
Dermatitis | 20 (57.2) | 8 (22.9) | 0 | 0 |
Renal dysfunction | 5 (14.3) | 1 (2.3) | 0 | 0 |
Others | 8 (22.9) | 2 (5.7) | 1 (2.3) | 0 |
Persistent adverse events | ||||
Xerostomia | 25 (71.4) | 2 (5.7) | 0 | 0 |
Dysphagia | 20 (57.1) | 0 | 0 | 0 |
Neck fibrosis | 7 (20.0) | 0 | 0 | 0 |
Study | Chemotherapy protocol (radiation dose) | No. of patients | Disease control rate (CR+PR, %) | Overall survival (%) | Stage |
---|---|---|---|---|---|
Present study | Cisplatin 30 mg/m2 at days 1, 8 and 15 every 4 wk during RT (70-72 Gy) | 35 | 94.30 | 51.2 (3 yr) | IVa |
Homma et al. (2011) [15] | Weekly cisplatin 40 mg/m2 on 1, 2, 3, 5, 6, and 7 of RT (70 Gy) | 53 | 100 | 93.7 (2 yr) | II-IV |
Kose et al. (2011) [18] | Weekly cisplatin 30 mg/m2 during RT (50-70 Gy) | 32 | - | 75.0 (3 yr) | II-IV |
Otty et al. (2011) [17] | Cisplatin 40 mg/m2 for 6 wk | 62 | 88.70 | 64.5 (3 yr) | II-IV |
ECOG, Eastern Cooperative Oncology Group; HPV, human papillomavirus; PCR, polymerase chain reaction.
Values are presented as number (%). CR, complete response; PR, partial response; SD, stable disease; NA, not applicable. Two patients were unavailable for response evaluation because one patient died due to septic shock during chemoradiation and another refused to continue chemoradiation because of grade IV emesis.
Values are presented as number (%). Expired due to pneumonia with septic shock.
CR, complete response; PR, partial response; RT, radiation therapy.